StockNews.com Lowers Mesoblast (NASDAQ:MESO) to Sell

StockNews.com lowered shares of Mesoblast (NASDAQ:MESO) from a hold rating to a sell rating in a research report released on Monday morning.

A number of other research analysts have also recently weighed in on MESO. Cantor Fitzgerald reaffirmed an overweight rating on shares of Mesoblast in a research report on Thursday, June 20th. Piper Sandler raised shares of Mesoblast from a neutral rating to an overweight rating and lifted their price target for the company from $4.00 to $11.00 in a report on Tuesday, July 23rd.

Mesoblast Stock Performance

NASDAQ MESO opened at $6.51 on Monday. The business’s fifty day moving average is $6.96 and its 200 day moving average is $5.61. Mesoblast has a fifty-two week low of $1.61 and a fifty-two week high of $8.66. The company has a market capitalization of $743.30 million, a PE ratio of -5.81 and a beta of 3.48.

Institutional Trading of Mesoblast

Several institutional investors have recently made changes to their positions in MESO. Marshall Wace LLP bought a new position in Mesoblast in the 2nd quarter worth approximately $562,000. Chase Investment Counsel Corp bought a new position in shares of Mesoblast during the first quarter worth $298,000. XTX Topco Ltd bought a new position in shares of Mesoblast during the second quarter worth $103,000. Chapin Davis Inc. grew its stake in Mesoblast by 50.0% during the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock valued at $102,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Rathbones Group PLC bought a new stake in Mesoblast in the 2nd quarter valued at $95,000. Hedge funds and other institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.